Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy

被引:0
作者
Daniel L. Hertz
Siddharth Roy
John Jack
Alison A. Motsinger-Reif
Amy Drobish
L. Scott Clark
Lisa A. Carey
E. Claire Dees
Howard L. McLeod
机构
[1] University of Michigan College of Pharmacy,Department of Clinical, Social, and Administrative Sciences
[2] North Carolina State University,Department of Statistics
[3] North Carolina State University,Bioinformatics Research Center
[4] Lineberger Comprehensive Cancer Center,Division of Hematology
[5] Gentris Corp,Oncology, Department of Medicine, School of Medicine
[6] University of North Carolina at Chapel Hill,undefined
[7] Moffitt Cancer Center,undefined
来源
Breast Cancer Research and Treatment | 2014年 / 145卷
关键词
Paclitaxel; Pharmacogenetics; Breast cancer; Chemotherapy-induced peripheral neuropathy; ABCG1; Affymetrix DMET™ plus; CYP2C8; Race;
D O I
暂无
中图分类号
学科分类号
摘要
The development of paclitaxel-induced peripheral neuropathy (PIPN) is influenced by drug exposure and patient genetics. The purpose of this analysis was to expand on a previous reported association of CYP2C8*3 and PIPN risk by investigating additional polymorphisms in CYP2C8 and in hundreds of other genes potentially relevant to paclitaxel pharmacokinetics. Clinical data was collected prospectively in an observational registry of newly diagnosed breast cancer patients. Patients treated with paclitaxel-containing regimens were genotyped using the Affymetrix DMET™ Plus chip. Patients who carried the CYP2C8*2, *3, or *4 variant were collapsed into a low-metabolizer CYP2C8 phenotype for association with PIPN. Separately, all SNPs that surpassed quality control were assessed individually and as a composite of genetic ancestry for associations with PIPN. 412 paclitaxel-treated patients and 564 genetic markers were included in the analysis. The risk of PIPN was significantly greater in the CYP2C8 low-metabolizer group (HR = 1.722, p = 0.018); however, the influences of the *2 and *4 SNPs were not independently significant (*2: p = 0.847, *4: p = 0.408). One intronic SNP in ABCG1 (rs492338) surpassed the exploratory significance threshold for an association with PIPN in the Caucasian cohort (p = 0.0008) but not in the non-Caucasian replication group (p = 0.54). Substantial genetic variability was observed within self-reported racial groups but this genetic variability was not associated with risk of grade 2+ PIPN. The pharmacogenetic heterogeneity within a cohort of breast cancer patients is dramatic, though we did not find evidence that this heterogeneity directly influences the risk of PIPN beyond the contribution of CYP2C8*3.
引用
收藏
页码:245 / 254
页数:9
相关论文
共 254 条
[1]  
Diéras V(2004)Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer J Clin Oncol 22 4958-4965
[2]  
Fumoleau P(2008)Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer J Natl Cancer Inst 100 805-814
[3]  
Romieu G(2003)Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer J Clin Oncol 21 976-983
[4]  
Tubiana-Hulin M(1996)Motor neuropathy due to docetaxel and paclitaxel Neurology. 47 115-118
[5]  
Namer M(2003)Comparative neurotoxicity of weekly non-break paclitaxel infusions over 1 versus 3 h Anticancer Drugs 14 785-792
[6]  
Mauriac L(1994)Paclitaxel (taxol) induces cumulative mild neurotoxicity Eur J Cancer 30 1074-1077
[7]  
Martin M(2005)Association of paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer Clin Cancer Res 11 4843-4850
[8]  
Rodriguez-Lescure Ã(2013)CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity Clin Cancer Res 19 3316-3324
[9]  
Ruiz A(2013)Germline pharmacogenetics of paclitaxel for cancer treatment Pharmacogenomics 14 1065-1084
[10]  
Alba E(1994)Selective biotransformation of taxol to 6{alpha}-hydroxytaxol by human cytochrome P450 2C8 Cancer Res 54 5543-5546